Therapeuticsmd, INC 8-K filings

TherapeuticsMD reported a decrease in net income and license revenue for Q2 2026, alongside an increase in operating expenses, while continuing to explore strategic alternatives.

TherapeuticsMD announced its first quarter 2026 financial results, reporting a net income of $103 thousand and license revenues of $724 thousand, while continuing to evaluate strategic alternatives.

TherapeuticsMD, Inc. announced the appointment of Carr, Riggs & Ingram, L.L.C. as its new independent registered public accounting firm, effective January 15, 2026.

TherapeuticsMD, Inc. shareholders approved all five proposals at its 2025 Annual Meeting, including the election of directors and an increase in authorized common stock.

TherapeuticsMD, a pharmaceutical royalty company, reported a net income of $50 thousand for the third quarter of 2025, a significant improvement from a loss in the prior year.

TherapeuticsMD, a pharmaceutical royalty company, reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss in the prior year, driven by increased license revenue and reduced operating expenses.

TherapeuticsMD reported a net loss of $636,000 for Q1 2025, with license revenue increasing by 25.8% and the company continuing to evaluate strategic alternatives.

TherapeuticsMD initiates legal action against Mayne Pharma, alleging breach of contract and related claims.

TherapeuticsMD, now a royalty-based company, announced its full year 2024 financial results, showing a reduced net loss and increased license revenue.

TherapeuticsMD held its 2024 Annual Meeting on December 5, 2024, where shareholders elected four directors, approved executive compensation, and ratified the appointment of an independent auditor.

TherapeuticsMD announced a reduced net loss and increased license revenue for the third quarter of 2024, while continuing to explore strategic alternatives.

TherapeuticsMD has set the date for its 2024 Annual Meeting of Stockholders for December 5, 2024, and has announced revised deadlines for submission of stockholder proposals.

TherapeuticsMD reported a reduced net loss of $1.05 million for the second quarter of 2024, compared to a $2.4 million loss in the same period last year, as the company continues to explore strategic alternatives.

TherapeuticsMD reported a reduced net loss and lower operating expenses for the first quarter of 2024 as it continues to evaluate strategic alternatives.

TherapeuticsMD reported a net loss of $7.7 million for 2023, as it continues to evaluate strategic alternatives after transitioning to a royalty-based business.